+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Pancreatitis (AP)- Epidemiology Forecast - 2030

  • ID: 5264917
  • Report
  • January 2021
  • Region: Global
  • 65 pages
  • DelveInsight
This ‘Acute Pancreatitis (AP)-Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the Acute Pancreatitis (AP), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Acute Pancreatitis (AP) Disease Understanding

Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas that presents as severe upper abdominal pain, often accompanied by nausea and vomiting. In acute pancreatitis, which has numerous causes, inflammation of the pancreas occurs, which can lead to pancreatic cell death or necrosis and systemic inflammation, a precursor to organ failure. Normal pancreatic functions, such as the secretion of digestive enzymes required to break down food in the gut, are disabled.

It may range in severity from self-limiting, characterized by mild pancreatic edema, to severe systemic inflammation with pancreatic necrosis, organ failure and death. There are several clinical, laboratory, and radiologic risk factors and scoring systems that are used to predict severity of AP, but none is optimal. Severe complications arise due to the acute inflammatory response that takes place in the pancreas. These complications can lead to systemic inflammatory response syndrome, or SIRS, in which the function of other tissues including the lung are compromised. Approximately one third of patients with severe acute pancreatitis develop acute lung injury or ARDS. Lung failure accounts for 60% of deaths associated with acute pancreatitis in developed countries.

Acute pancreatitis usually begins with gradual or sudden pain in the upper abdomen that sometimes extends to the back. The pain may be mild at first and become worse after eating. The pain is often severe, constant, and commonly lasts for several days in the absence of treatment. A person with acute pancreatitis usually looks and feels very ill and needs immediate medical attention. Most cases require hospitalization for 3 to 5 days for close monitoring, pain control, and intravenous hydration. Other symptoms can include: swollen and tender abdomen, nausea and vomiting, fever and rapid pulse.

The diagnosis of acute pancreatitis requires at least 2 of the following: typical upper abdominal pain, elevated levels of amylase or lipase, and confirmatory findings from cross-sectional imaging analysis. Although, the disease is usually confirmed by medical history, physical examination, and typically a blood test (amylase or lipase) for the pancreas' digestive enzymes. Blood amylase or lipase levels are typically elevated 3 times the normal level during acute pancreatitis. In some cases, when the blood tests are not elevated, and the diagnosis is still in question, abdominal imaging, such as a computed tomography (CT) scan, might be performed.

Acute Pancreatitis (AP) Epidemiology

The Acute Pancreatitis (AP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute Pancreatitis (AP) epidemiology segmented as the Diagnosed Incident Cases of Acute Pancreatitis (AP), Gender-specific cases of Acute Pancreatitis (AP), Diagnosed Incident Cases of Acute Pancreatitis (AP) by Etiology and Diagnosed Incident Cases of Acute Pancreatitis (AP) by Severity. The report includes the Incident scenario of Acute Pancreatitis (AP) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Acute Pancreatitis (AP) Epidemiology

The epidemiology segment also provides the Acute Pancreatitis (AP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total Incident population of Acute Pancreatitis (AP) Associated in 7MM countries was estimated to be 502,390 cases in 2020 and expected to increase at a CAGR of 0.47% for the study period i.e. 2017-2030.
  • As per the estimates, United States had the highest Incident population of Acute Pancreatitis (AP)
  • Among the EU5 countries, Germany had the highest Incident population of Acute Pancreatitis (AP). On the other hand, Italy had the lowest number of cases as 12,423 cases in 2020
Scope of the Report
  • Acute Pancreatitis (AP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Acute Pancreatitis (AP) Epidemiology Report and Model provide an overview of the risk factors and global trends of Acute Pancreatitis (AP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Acute Pancreatitis (AP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute Pancreatitis (AP)
  • The report provides the segmentation of the Acute Pancreatitis (AP) epidemiology by Incident Cases of Acute Pancreatitis (AP) in 7MM
  • The report provides the segmentation of the Acute Pancreatitis (AP) epidemiology by Etiology, gender and severity-specific diagnosed incident Cases of Acute Pancreatitis (AP) in 7MM
Report Highlights
  • 11-year Forecast of Acute Pancreatitis (AP) epidemiology
  • 7MM Coverage
  • Total Incident Cases of Acute Pancreatitis (AP)
  • Incident Cases according to segmentation: Severity-specific Incidence of Acute Pancreatitis (AP)
KOL Views

The publisher interviews KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population about Acute Pancreatitis (AP)?
  • What are the key findings of Acute Pancreatitis (AP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients with Acute Pancreatitis (AP) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of Acute Pancreatitis (AP)?
  • What are the currently available treatments for Acute Pancreatitis (AP)?
Reasons to Buy

The Acute Pancreatitis (AP) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Acute Pancreatitis (AP) market
  • Quantify patient populations in the global Acute Pancreatitis (AP) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acute Pancreatitis (AP) therapeutics in each of the markets covered
  • Understand the magnitude of Acute Pancreatitis (AP) population by its Incident cases
  • Understand the magnitude of Acute Pancreatitis (AP) population by its Severity-specific cases
  • The Acute Pancreatitis (AP) epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Acute Pancreatitis (AP) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

According to various research studies, acute pancreatitis (AP) is the twelfth most common gastrointestinal presentation to the emergency department (ED) in the United States.
Note: Product cover images may vary from those shown
1 Key Insights

2 Executive Summary for Acute Pancreatitis

3 SWOT Analysis for Acute Pancreatitis

4 Disease Background and Overview
4.1 Introduction
4.2 Classification
4.3 Causes
4.4 Symptoms and Complications
4.5 Pathophysiology
4.6 Diagnosis
4.7 Biomarkers

5 Epidemiology and Patient Population
5.1 Key Findings

6 Total Diagnosed Incident Population of Acute Pancreatitis

7 Country Wise-Epidemiology of Acute Pancreatitis
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.1.1 Total Diagnosed Incident Cases of AP in the United States
7.1.1.2 Diagnosed Incidence of AP by Etiology in the United States
7.1.1.3 Diagnosed Incidence of AP by Severity in the United States
7.1.1.4 Diagnosed Incidence of AP by Gender in the United States
7.1.1.5 Recurrent AP Cases in the United States
7.2 EU5 Countries
7.2.1 Germany
7.2.1.1 Total Diagnosed Incident Cases of AP in Germany
7.2.1.2 Diagnosed Incidence of AP by Etiology in Germany
7.2.1.3 Diagnosed Incidence of AP by Severity in Germany
7.2.1.4 Diagnosed Incidence of AP by Gender in Germany
7.2.1.5 Recurrent AP Cases in Germany
7.2.2 France
7.2.2.1 Total Diagnosed Incident Cases of AP in France
7.2.2.2 Diagnosed Incidence of AP by Etiology in France
7.2.2.3 Diagnosed Incidence of AP by Severity in France
7.2.2.4 Diagnosed Incidence of AP by Gender in France
7.2.2.5 Recurrent AP Cases in France
7.2.3 Italy
7.2.3.1 Total Diagnosed Incident Cases of AP in Italy
7.2.3.2 Diagnosed Incidence of AP by Etiology in Italy
7.2.3.3 Diagnosed Incidence of AP by Severity in Italy
7.2.3.4 Diagnosed Incidence of AP by Gender in Italy
7.2.3.5 Recurrent AP Cases in Italy
7.2.4 Spain
7.2.4.1 Total Diagnosed Incident Cases of AP in Spain
7.2.4.2 Diagnosed Incidence of AP by Etiology in Spain
7.2.4.3 Diagnosed Incidence of AP by Severity in Spain
7.2.4.4 Diagnosed Incidence of AP by Gender in Spain
7.2.4.5 Recurrent AP Cases in Spain
7.2.5 The United Kingdom
7.2.5.1 Total Diagnosed Incident Cases of AP in the UK
7.2.5.2 Diagnosed Incidence of AP by Etiology in the UK
7.2.5.3 Diagnosed Incidence of AP by Severity in the UK
7.2.5.4 Diagnosed Incidence of AP by Gender in the UK
7.2.5.5 Recurrent AP Cases in the UK
7.3 Japan
7.3.1 Assumptions and Rationale
7.3.2 Total Diagnosed Incident Cases of AP in Japan
7.3.3 Diagnosed Incidence of AP by Etiology in Japan
7.3.4 Diagnosed Incidence of AP by Severity in Japan
7.3.5 Diagnosed Incidence of AP by Gender in Japan
7.3.6 Recurrent AP Cases in Japan

8 Appendix
8.1 Report Methodology

9 Publisher Capabilities

10 Disclaimer

11 About the Publisher

List of Tables
Table 1: Summary of Acute Pancreatitis Market, Epidemiology, and Key Events (2017-2030)
Table 2: Definition of severity in Acute Pancreatitis
Table 3: Revised definitions of morphological features of Acute Pancreatitis
Table 4: Causes of Acute Pancreatitis
Table 5: Complications of Acute Pancreatitis
Table 6: Diagnosed Incident Population of Acute Pancreatitis in 7MM (2017-2030)
Table 7: Total Diagnosed Incident Cases of AP in the United States (2017-2030)
Table 8: Diagnosed Incidence of AP by Etiology in the United States (2017-2030)
Table 9: Diagnosed Incidence of AP by Severity in the United States (2017-2030)
Table 10: Diagnosed Incidence of AP by Gender in the United States (2017-2030)
Table 11: Recurrent AP Cases in the United States (2017-2030)
Table 12: Total Diagnosed Incident Cases of AP in Germany (2017-2030)
Table 13: Diagnosed Incidence of AP by Etiology in Germany (2017-2030)
Table 14: Diagnosed Incidence of AP by Severity in Germany (2017-2030)
Table 15: Diagnosed Incidence of AP by Gender in Germany (2017-2030)
Table 16: Recurrent AP Cases in Germany (2017-2030)
Table 17: Total Diagnosed Incident Cases of AP in France (2017-2030)
Table 18: Diagnosed Incidence of AP by Etiology in France (2017-2030)
Table 19: Diagnosed Incidence of AP by Severity in France (2017-2030)
Table 20: Diagnosed Incidence of AP by Gender in France (2017-2030)
Table 21: Recurrent AP Cases in France (2017-2030)
Table 22: Total Diagnosed Incident Cases of AP in Italy (2017-2030)
Table 23: Diagnosed Incidence of AP by Etiology in Italy (2017-2030)
Table 24: Diagnosed Incidence of AP by Severity in Italy (2017-2030)
Table 25: Diagnosed Incidence of AP by Gender in Italy (2017-2030)
Table 26: Recurrent AP Cases in Italy (2017-2030)
Table 27: Total Diagnosed Incident Cases of AP in Spain (2017-2030)
Table 28: Diagnosed Incidence of AP by Etiology in Spain (2017-2030)
Table 29: Diagnosed Incidence of AP by Severity in Spain (2017-2030)
Table 30: Diagnosed Incidence of AP by Gender in Spain (2017-2030)
Table 31: Recurrent AP Cases in Spain (2017-2030)
Table 32: Total Diagnosed Incident Cases of AP in the United Kingdom (2017-2030)
Table 33: Diagnosed Incidence of AP by Etiology in the United Kingdom (2017-2030)
Table 34: Diagnosed Incidence of AP by Severity in the United Kingdom (2017-2030)
Table 35: Diagnosed Incidence of AP by Gender in the United Kingdom (2017-2030)
Table 36: Recurrent AP Cases in the United Kingdom (2017-2030)
Table 37: Total Diagnosed Incident Cases of AP in Japan (2017-2030)
Table 38: Diagnosed Incidence of AP by Etiology in Japan (2017-2030)
Table 39: Diagnosed Incidence of AP by Severity in Japan (2017-2030)
Table 40: Diagnosed Incidence of AP by Gender in Japan (2017-2030)
Table 41: Recurrent AP Cases in Japan (2017-2030)

List of Figures
Figure 1: Activation of digestive enzymes within the acinar cell leads to pathological changes.
Figure 2: Indications for Laboratory and Radiologic Testing in Pancreatitis
Figure 3: Signs and Tests for the Diagnosis of Pancreatitis
Figure 4: Diagnosed Incident Population of Acute Pancreatitis in 7MM (2017-2030)
Figure 5: Total Diagnosed Incident Cases of AP in the United States (2017-2030)
Figure 6: Diagnosed Incidence of AP by Etiology in the US (2017-2030)
Figure 7: Diagnosed Incidence of AP by Severity in the United States (2017-2030)
Figure 8: Diagnosed Incidence of AP by Gender in the United States (2017-2030)
Figure 9: Recurrent AP Cases in the United States (2017-2030)
Figure 10: Total Diagnosed Incident Cases of AP in Germany (2017-2030)
Figure 11: Diagnosed Incidence of AP by Etiology in Germany (2017-2030)
Figure 12: Diagnosed Incidence of AP by Severity in Germany (2017-2030)
Figure 13: Diagnosed Incidence of AP by Gender in Germany (2017-2030)
Figure 14: Recurrent AP Cases in Germany (2017-2030)
Figure 15: Total Diagnosed Incident Cases of AP in France (2017-2030)
Figure 16: Diagnosed Incidence of AP by Etiology in France (2017-2030)
Figure 17: Diagnosed Incidence of AP by Severity in France (2017-2030)
Figure 18: Diagnosed Incidence of AP by Gender in France (2017-2030)
Figure 19: Recurrent AP Cases in France (2017-2030)
Figure 20: Total Diagnosed Incident Cases of AP in Italy (2017-2030)
Figure 21: Diagnosed Incidence of AP by Etiology in Italy (2017-2030)
Figure 22: Diagnosed Incidence of AP by Severity in Italy (2017-2030)
Figure 23: Diagnosed Incidence of AP by Gender in Italy (2017-2030)
Figure 24: Recurrent AP Cases in Italy (2017-2030)
Figure 25: Total Diagnosed Incident Cases of AP in Spain (2017-2030)
Figure 26: Diagnosed Incidence of AP by Etiology in Spain (2017-2030)
Figure 27: Diagnosed Incidence of AP by Severity in Spain (2017-2030)
Figure 28: Diagnosed Incidence of AP by Gender in Spain (2017-2030)
Figure 29: Recurrent AP Cases in Spain (2017-2030)
Figure 30: Total Diagnosed Incident Cases of AP in the UK (2017-2030)
Figure 31: Diagnosed Incidence of AP by Etiology in the UK (2017-2030)
Figure 32: Diagnosed Incidence of AP by Severity in the UK (2017-2030)
Figure 33: Diagnosed Incidence of AP by Gender in the UK (2017-2030)
Figure 34: Recurrent AP Cases in the UK (2017-2030)
Figure 35: Total Diagnosed Incident Cases of AP in Japan (2017-2030)
Figure 36: Diagnosed Incidence of AP by Etiology in Japan (2017-2030)
Figure 37: Diagnosed Incidence of AP by Severity in Japan (2017-2030)
Figure 38: Diagnosed Incidence of AP by Gender in Japan (2017-2030)
Figure 39: Recurrent AP Cases in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll